Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2175-2181

  Redondo, Andrés ^a   Martínez, Virginia ^a   Zamora, Pilar ^a   Castelo, Beatriz ^a   Pinto, Alvaro ^a   Cruz, Patricia ^a   Higuera, Oliver ^a   Mendiola, Marta ^a   Hardisson, David ^a   Espinosa, Enrique ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Advanced breast cancer; Bevacizumab; First line; Hormone therapy; Maintenance

Indexed keywords

BEVACIZUMAB; ESTROGEN RECEPTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 84919384654     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S70654     Document Type: Article

References (14)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676.
2. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–3247.
3. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–1260.
4. Liu Y, Tamimi RM, Collins LC, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat. 2011;129:175–184.
5. Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol. 2012;2012:261750.
6. Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep. 2012;14:1–11.
7. Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012;133:1067–1075.
8. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22:595–602.
9. Llombart-Cussac A, Pivot XB, Biganzoli L, et al. A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: analysis from the ATHENA trial. J Clin Oncol. 2013;31:555.
10. Regierer AC, Wolters R, Ufen MP, et al. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol. 2014;25:633–638.
11. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat. 2011;130:133–143.
12. Fabi A, Russillo M, Ferretti G, etal. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer. 2012;12:482.
13. Yardley DA, Burris HA 3rd, Clark BL, et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer. 2011; 11: 146–152.
14. Loibl S, De la Haba J, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer. Final analysis of the LEA study. Poster presented at: 2013 European Cancer Congress; September 27–October 1, 2013; Amsterdam.